Search

everythinglearnresearchcommunity

for

Search:↓

SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.

Scube3, a potential hair loss treatment, is unlikely to be released because it was given to a startup company, Amplifica, which may go bankrupt and fail to bring the treatment to market. Amplifica is prioritizing other treatments over Scube3, which could lead to financial loss and the end of Scube3's development.

A user's journey with hair loss, starting with finasteride at age 17 and switching to dutasteride at 18. The post provides insight on how minoxidil helped initially but quitting it caused some regrowth that was regained when switching to dutasteride. There is also discussion about starting finasteride as young as 17 years old for those who may be worried about potential physical development issues.

Dr. Kang-Yell Choi's company, CK Regeon, is developing a drug called KY19382 for hair regeneration, which involves creating fine wounds to activate stem cells. The drug is in the formulation development stage, targeting markets like the US and Korea.

You cannot donate blood if you are taking finasteride or dutasteride due to potential risks to pregnant women. Finasteride has a shorter wait time to donate blood compared to dutasteride, and both oral and topical forms can disqualify you from donating.

The conversation is about acquiring GT20029 for hair loss treatment. The user is looking for information on how to obtain it.

Hair loss discussion mentions Verterporfin for scar-free healing and hair follicle regeneration. Human study expected within 2 years.

User "Ant1pal" shares progress pictures of hair regrowth using Minoxidil, Estradiol valerate, and Spironolactone. Users discuss potential side effects and the possibility of localizing estrogen to hair follicles for better treatment.

The conversation discusses hair loss treatments, including Minoxidil, finasteride, and RU58841. It highlights an interview with Stemson Therapeutics CEO Geoff Hamilton about advancements in hair cloning technology.

A 17-year-old experiencing hair loss due to hard water was advised by a dermatologist to use a treatment containing Minoxidil and vitamins. A respondent confirmed the treatment's safety but warned that discontinuing Minoxidil could worsen hair loss.

Finasteride may affect liver function and cortisol levels, potentially linking it to non-alcoholic fatty liver disease (NAFLD). More research is needed to understand this connection fully.

The conversation discusses potential new treatments for androgenetic alopecia (AGA), including verteporfin, pyrilutamide, and hair cloning. There is optimism about scientific advancements providing alternatives to minoxidil and finasteride.

The conversation is about hair loss treatments, including minoxidil, finasteride, dutasteride, tretinoin, stemoxydine, adenosine, castor oil, baicalin, and bimatoprost. The user shares their nightly and morning routines and discusses the role of DHT in hair loss.

The conversation is about updates on Scube3 related to hair loss. Specific treatments mentioned are Minoxidil, Finasteride, and RU58841.

A 16-year-old experiencing hair loss seeks treatment advice. They decide to start with Serioxyl, Ketoconazole shampoo, and Eucapil, considering Minoxidil and Finasteride for later use.

Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.

The user is experiencing hair loss and is using Minoxidil once a day. They suspect Vitamin D deficiency and Seborrheic Dermatitis might be contributing factors.

A user is seeking alternatives to finasteride for hair loss during a planned break for family planning reasons. They inquire about pyrilutamide, cosmern, and other potential future treatments.

JW0061 shows superior hair growth results compared to existing treatments, with significant increases in hair follicles. The Wnt/β-catenin pathway is crucial for hair growth, and JW0061 activates this pathway effectively.

A user with stage 1 hair loss is inquiring about the release date of GT20029, hoping to use it instead of Minoxidil and finasteride, as they believe it has better results. They want to know if it will be available in the next couple of years.

The conversation discusses disappointment with the hair loss treatment KX-826 but notes that the company Kintor is still focused on developing and commercializing it, as stated in their 2023 annual report. The user questions the effectiveness of KX-826 in comparison to minoxidil's role in improving hair thickness and appearance.

A 16-year-old has been using microneedling, rosemary oil, coconut oil and egg mask, Nizoral shampoo, saw palmetto, and supplements for hair loss and is asking if there's progress. It's suggested to replace some oils with minoxidil, continue saw palmetto, and possibly start finasteride at 18.

The conversation discusses a new hair growth treatment that showed a 14 hairs/cm2 increase in a trial, with mixed opinions on its effectiveness and potential cost. Some users are hopeful about combining it with existing treatments like oral minoxidil for better results.

A user from China is participating in a clinical trial for Pyrilutamid, a potential hair loss treatment originally developed for prostate cancer. They've experienced no side effects except initial scalp itchiness, and will share results after the year-long trial.

Brian Dye's theory links skeletal malocclusion type II to hair loss, suggesting it's a blood flow issue. Treatments mentioned include minoxidil, finasteride, and anti-inflammatory drugs like benaxoprofen.

Tretinoin may enhance minoxidil's effectiveness for those not responding to minoxidil alone, but it could reduce efficacy for some who are already responding to minoxidil. Tretinoin requires careful use, including skin moisturizing and sun protection due to increased sensitivity.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Update on HMI-115 clinical trial expected in July or August.

User tried Propecia and topical finasteride but experienced side effects. Switched to Dutasteride and oral Minoxidil, then added CosmeRNA for hair loss treatment.

SCUBE3 clinical trials for hair loss treatment to start this year. Treatment may involve regular, painless scalp injections to maintain hair growth.

Hair loss discussion includes Minoxidil, finasteride, and RU58841 treatments. Hope Medicine has a new CEO, possibly leading to HMI's termination.